E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/17/2016 in the Prospect News Structured Products Daily.

New Issue: JPMorgan prices $676,000 contingent interest autocallables linked to pharma stocks

By Angela McDaniels

Tacoma, Wash., May 17 – JPMorgan Chase Financial Co. LLC priced $676,000 autocallable contingent interest notes due Nov. 20, 2017 linked to the least performing of the American Depositary Shares of Teva Pharmaceutical Industries Ltd., the common stock of Pfizer Inc. and the common stock of Gilead Sciences, Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by JPMorgan Chase & Co.

Each quarter, the notes will pay a contingent coupon at an annual rate of 15% if each stock closes at or above its trigger value, 65% of its initial price, on the review date for that quarter.

The notes will be automatically called at par if each stock closes at or above its initial price on any quarterly review other than the first or final review dates.

The payout at maturity will be par unless any stock finishes below its trigger value, in which case investors will be fully exposed to the decline of the worst-performing stock.

J.P. Morgan Securities LLC is the agent.

Issuer:JPMorgan Chase Financial Co. LLC
Guarantor:JPMorgan Chase & Co.
Issue:Autocallable contingent interest notes
Underlying stocks:Teva Pharmaceutical Industries Ltd. (Symbol: TEVA), Pfizer Inc. (Symbol: PFE) and Gilead Sciences, Inc. (Symbol: GILD)
Amount:$676,000
Maturity:Nov. 20, 2017
Coupon:15%, payable quarterly if each stock closes at or above trigger value on review date for that quarter
Price:Par
Payout at maturity:Par plus contingent coupon if each stock finishes at or above trigger value; otherwise, exposure to decline of worst-performing stock
Call:Automatically at par plus contingent coupon if each stock closes at or above initial price on any quarterly review date other than first or final ones
Initial prices:$50.30 for Teva, $33.19 for Pfizer and $82.70 for Gilead
Trigger values:$32.695 for Teva, $21.5735 for Pfizer and $53.755 for Gilead; 65% of initial prices
Pricing date:May 13
Settlement date:May 20
Underwriters:J.P. Morgan Securities LLC
Fees:2.25%
Cusip:46646EBM3

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.